If you've been curious about peptide therapy but hesitant about sourcing it safely, there's real news to know. The FDA's compounding advisory committee just gave a favorable vote to six peptides, including BPC-157 and TB-500, moving them toward legal, pharmacy-prepared access under a provider's care. Here's what the decision actually means, what's still ahead, and how to think about timing.